88338T104
Theravance Biopharma, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that makes YUPELRI (revefenacin), a once-daily nebulized medicine that helps people with COPD breathe more easily, sold in the US with partner Viatris. It grew out of Theravance, Inc., founded in 1996, which split in 2014 into two public companies, with Theravance Biopharma keeping the respiratory drug pipeline. Its name blends "therapy" and "advance"—fitting for a firm built on advancing medicine.
CUSIP: 88338T104HealthcareUS2 holders
Total Value
$311.77M
Total Shares
14.02M
Net Share Change
+464.0K
Activity
1 buying
Investor
Value
Shares
Weight
Change
